Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
2014 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.
Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative. Guo S, et al. Front Aging Neurosci. 2017 May 18;9:146. doi: 10.3389/fnagi.2017.00146. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28572766 Free PMC article.
In this study, 158 subjects (72 NC, 46 sMCI, and 40 cMCI) were selected from the Alzheimer's Disease Neuroimaging Initiative. A sparse-constrained regression model based on the l2-1-norm was introduced to reduce the feature dimensionality and retrieve essential features fo …
In this study, 158 subjects (72 NC, 46 sMCI, and 40 cMCI) were selected from the Alzheimer's Disease Neuroimaging Initiative. A spars …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate …
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's
[Assistant Professor Lazar' Moiseevich Rozenfel'd; 60 years of his medical, scientific pedagogical and social activities].
NIKITINA AI, GITEL'MAN VM. NIKITINA AI, et al. Vestn Otorinolaringol. 1956 May-Jun;18(3):87. Vestn Otorinolaringol. 1956. PMID: 13338057 Russian. No abstract available.
Feedback